IMCR — Immunocore Holdings plc
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1671927 ·
Last close
$27.81
Market Cap
$1.43B
52W High
$40.72
52W Low
$27.31
ADV30
512,568
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 102,222,000 | 101,546,000 | -13,609,000 | -14,222,000 | 1,129,239,000 | 512,245,000 | 709,533,000 |
| Jun 2026 | 115,927,000 | 114,839,000 | -2,996,000 | -808,000 | 1,119,422,000 | 484,920,000 | 699,624,000 |
| Mar 2026 | 106,677,000 | 106,243,000 | 7,280,000 | 12,971,000 | 1,072,095,000 | 452,675,000 | 678,422,000 |
| Dec 2025 | 104,478,000 | 101,775,000 | -19,691,000 | -30,060,000 | 1,067,269,000 | 467,709,000 | 686,236,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,958,000
Investing CF
$7,805,000
Financing CF
$23,291,000
CapEx
$-6,195,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.37
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-819,112,000
Inventory
$7,791,000
Receivables
$95,350,000
ST Investments
$395,291,000
EBIT TTM
$9,969,000
Pretax Income TTM
$-2,732,000
Interest Exp TTM
$12,701,000
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$430,775,008
EBITDA
$756,000
Free Cash Flow
$35,592,124
Enterprise Value
$1,150,690,176
Total Cash
$880,211,008
Total Debt
$434,959,008
Shares Out
51,498,617
Trailing EPS
$-0.64
Book Value
$7.52
ROE
-4.5%
ROA
-0.2%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 400,016,000 | -45,353,000 | -35,514,000 | 1,067,269,000 | 686,236,000 | 381,033,000 | -10,712,000 |
| Dec 2024 | 310,202,000 | -70,461,000 | -51,087,000 | 1,009,506,000 | 648,790,000 | 360,716,000 | 26,061,000 |
| Dec 2023 | 249,428,000 | -59,649,000 | -55,287,000 | 597,001,000 | 228,158,000 | 368,843,000 | 2,940,000 |
| Dec 2022 | 174,361,000 | -51,708,000 | -52,543,000 | 526,762,000 | 187,859,000 | 338,903,000 | -49,209,000 |
TTM Snapshot
Revenues TTM
$430,775,000
NetIncome TTM
$-18,074,000
OpCashFlow TTM
—
Assets (Latest)
$1,119,422,000
Forward EPS
$-0.99
Max Pain — expiry 2027-04-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $20.00 · spot: $27.51 · call volume: 1,080 · put volume: 2
Expected Move to 2027-04-16:
±$8.55
(31.08%) —
implied range
$18.96 –
$36.06
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
| MESO | MESOBLAST LTD | $1.55B | $11.91 | — |
| ALVO | Alvotech | $1.56B | $4.37 | — |
| NVAX | NOVAVAX INC | $1.31B | $7.96 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.30B | $4.00 | — |
News headlines (Yahoo Finance, 1h cache)
Immunocore to present at upcoming investor conferences
2026-11-09 12:00 · Yahoo
Immunocore presents promising data from Phase 1/2 trial cohort evaluating brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma
2026-11-06 17:00 · Yahoo
Immunocore reports third quarter financial results and provides a business update
2026-11-06 14:00 · Yahoo
Immunocore will present Phase 1 data for brenetafusp plus KIMMTRAK® (tebentafusp-tebn) in metastatic uveal melanoma, during a late-breaking oral session at the 2026 SITC meeting
2026-10-29 13:00 · Yahoo
Should First Type 1 Diabetes Dosing Require Action From Immunocore Stock Investors?
2026-10-29 00:14 · Yahoo
GeneDx Holdings And 2 Other Top Healthcare Stocks
2026-10-17 15:11 · Yahoo
Immunocore announces first patient dosed in the Phase 1 trial of IMC-S118AI – its first tissue-specific autoimmune candidate – for patients with type 1 diabetes
2026-10-15 11:00 · Yahoo
Top 3 Healthcare Stocks To Watch In October 2026
2026-10-10 14:17 · Yahoo
Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
2026-09-15 15:22 · Yahoo
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
2026-09-14 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.